My key takeaway (with LinkedIn links, Kilian Kelly is signalling...

My key takeaway (with LinkedIn links, Kilian Kelly is signalling a potentially big few months ahead for Cynata Therapeutics, with a GVHD update expected within three months and osteoarthritis not far behind in the next two to three.

If that lands as anticipated, it should set up a potential TGA submission for DFU shortly after.

We’ve already seen an early move, with the share price lifting ~10% into the end of last week. That could be the first sign of momentum building toward valuations that better reflect the underlying potential, and perhaps a return to levels we saw before a pandemic, two major wars and two Trump presidencies...

Also worth noting Cynata cracked the top 20 performing microcaps last week, coming in at #19.

Feels like we’re moving out of the “story” phase and into the “delivery” phase, hoping to see the share price take off from here.... PLEASE!!!